Omeros (OMER) Cut to “Sell” at ValuEngine

Omeros (NASDAQ:OMER) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

OMER has been the subject of a number of other research reports. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Thursday, December 14th. Maxim Group set a $24.00 target price on shares of Omeros and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Cowen cut shares of Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Finally, Zacks Investment Research cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $30.38.

Shares of Omeros (OMER) traded down $2.40 during trading on Wednesday, hitting $11.25. 5,700,000 shares of the stock were exchanged, compared to its average volume of 730,690. The company has a market capitalization of $540.04, a PE ratio of -8.72 and a beta of 3.30. Omeros has a 52 week low of $10.51 and a 52 week high of $27.09. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ingalls & Snyder LLC lifted its position in Omeros by 3.4% during the fourth quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock worth $103,664,000 after purchasing an additional 174,204 shares during the period. Vanguard Group Inc. lifted its position in Omeros by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after purchasing an additional 94,280 shares during the period. State Street Corp lifted its position in Omeros by 7.3% during the second quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after purchasing an additional 66,827 shares during the period. Capital Analysts LLC lifted its position in Omeros by 885.6% during the fourth quarter. Capital Analysts LLC now owns 590,849 shares of the biopharmaceutical company’s stock worth $36,125,000 after purchasing an additional 530,899 shares during the period. Finally, Northern Trust Corp lifted its position in Omeros by 6.4% during the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after purchasing an additional 34,328 shares during the period. 50.24% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Omeros (OMER) Cut to “Sell” at ValuEngine” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/omeros-omer-cut-to-sell-at-valuengine.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply